ClinicalTrials.Veeva

Menu

Immunotherapy of Advanced Hepatitis B Related Hepatocellular Carcinoma With γδT Cells

B

Beijing 302 Hospital

Status and phase

Unknown
Phase 1

Conditions

Hepatocellular Carcinoma

Treatments

Biological: autologous γδT cells

Study type

Interventional

Funder types

Other

Identifiers

NCT04032392
Beijing302-013

Details and patient eligibility

About

To evaluate the safety, tolerability and efficacy of autologous γδT cells in the treatment of advanced hepatitis B-related hepatocellular carcinoma.

Full description

This is a single-centre, non-randomised, open label, no control, prospective clinical trial. The study will include the following sequential phases: sign informed consent, γδT cells pre-culture, fresh biopsy and screening, apheresis, γδT cells preparation, treatment and follow-up. The study will evaluate the safety, tolerability and efficacy of autologous γδT cells in patients with advanced hepatitis B related hepatocellular carcinoma (HCC) which are refractory to current treatment.

Stage I comprising a safety cohort of patients to identify a safe dose, Stage II comprising an expanded patient group for response signal identification, Stage III to confirm efficacy and safety.

Enrollment

20 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Patients should sign informed consent form voluntarily and comply with the requirements of this study.
  2. Gender unlimited, age 18 to 70 years old.
  3. Hepatocellular carcinoma histopathology proven by liver fresh biopsy.
  4. According to the 2018 edition of the EASL guidelines for primary liver cancer, patients were diagnosed with advanced HBV-related hepatocellular carcinoma (BCLC stage B and C) by pathology and imaging; all patients required antiviral therapy with nucleoside analogues; other treatments (e.g. interventional therapy) at least 2 weeks prior to γδT cell infusion; patients can take the first- or second-line targeted drugs recommended by the guidelines, such as lenvatinib or sorafenib.
  5. Liver function: Child-Pugh class A/B (5-9), Eastern Cooperative Oncology Group (ECOG) Performance status 0-2.
  6. Expected survival ≥ 6 months.
  7. Male and female of reproductive potential must agree to use birth control during the study and for at least 30 days post study.

Exclusion criteria

  1. Combine other viral liver diseases or other liver disease patients.
  2. Acute infection, gastrointestinal bleeding, etc. occurred within 30 days before screening.
  3. Pregnant or lactating women; patients after organ transplantation; patients with severe autoimmune diseases; patients with uncontrolled infectious diseases.
  4. Dysfunction of major organs; patient white blood cell count <1.0×10e9/L, platelet count <60×10e9/L, hemoglobin <86g/L, prothrombin time (INR) >2.3, or prolonged clotting time >6 seconds, serum albumin <28g/L, total bilirubin >51mmol/L, ALT/AST >5 times the upper limit of normal, creatinine >1.5 times the upper limit of normal.
  5. Combined with other serious organic diseases, mental illnesses, including any uncontrolled clinically significant systemic diseases such as urinary, circulatory, respiratory, neurological, psychiatric, digestive, endocrine and immune diseases.
  6. Allergic constitution, history of allergies to blood products, known to be allergic to test substances.
  7. Immunosuppressive or systemic cytotoxic drugs may require within six months prior to screening or during treatment; 6 months prior to screening accepted other cell therapies including NK, CIK, DC, CTL and stem cell therapy etc.; immunotherapy such as PD-1 and PD-L1 antibodies.
  8. Patients currently participating in other clinical trials who may violate this treatment plan and observations.
  9. Those who are unable or unwilling to provide informed consent or who are unable to comply with the research requirements.
  10. Any situation that investigators believe the risk of the subjects is increased or results of the trial are disturbed: patients with any serious acute or chronic physical or mental illness, or laboratory abnormalities.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

20 participants in 1 patient group

Autologous γδT cells
Experimental group
Description:
Subjects will receive 3 cycles of γδT cells treatments, at four-week intervals, each cycle has 2 infusions. Dose escalation subjects will receive 6 infusions with dose of γδT cells escalation from 1×10e9 to 6×10e9. Constant dose subjects will have single infusion intravenously at a target dose of 1\~2×10e9 γδT cells.
Treatment:
Biological: autologous γδT cells

Trial contacts and locations

2

Loading...

Central trial contact

Yuanyuan Li, Dr

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems